Sensorial Neurodegeneration

Group leader: Cristina Irigoyen Laborra, Ph.D.

OSI Donostialdea cristina.irigoyenlaborra@osakidetza.eus
Dr. Cristina Irigoyen Laborra has a Degree in Medicine earned at the University of Navarra. Having specialised in Ophthalmology at Deusto University Hospital (Donostialdea IHO) in 2009 and obtained the EBOD (European Board of Ophthalmology) and ICO (International Council of Ophthalmology) certificates, she completed a fellowship in vitreoretinal surgery at the Royal Liverpool University Hospital. She has a PhD from the University of the Basque Country (UPV/EHU) and is Professor at the UPV/EHU Faculty of Medicine. Today she works at the Donostia University Hospital and at the Policlínica Gipuzkoa in San Sebastián, in the sub-speciality of medical and surgical retina. She is Leader of the Sensory Neurodegeneration Research Group at the Biodonostia HRI and dedicates a great part of her care and research work to the study of hereditary retinal dystrophies.

Aims and lines of research

Vision is one of the human being’s main sensory skills. The Research Group is focusing its study on diseases that affect our sense of sight, with Retinitis Pigmentosa as its main line of research.

Retinitis Pigmentosa is the most common inherited retinal degenerative disorder, with a worldwide prevalence of approximately 1 in every 4000 individuals. It is characterised by progressive dysfunction associated with the loss of rods and/or cones leading to atrophy of the retina and loss of vision. There is wide genetic heterogeneity within Retinitis Pigmentosa with over 80 genes identified to date. Most cases are monogenic and the genetic causes of approximately 35% of Retinitis Pigmentosa cases are currently unknown. Their molecular characterisation represents a real challenge. From a therapy point of view, there is no standardised, effective treatment for this eye disease right now but the discovery of molecular causes has allowed different trials to be designed on animal models and more recently on humans, with promising results.

Another area of study focuses on cataracts that represent the main cause of loss of vision in people over 55 years old worldwide. This is a multi-factor process where modifications to the structural crystalline proteins bring about aggregation, fragmentation and precipitation processes leading to the cataract forming. Right now, the only effective treatment is surgery. This is one of the most frequent outpatient surgeries carried out in industrialised countries and the most common outpatient procedure in Spain where over 260,000 cataract operations are performed each year, costing over 260 million Euros/year.

Furthermore, working with pharmacometric and software companies, the Research Group is developing computer simulated predictors of ocular pharmacodynamics in order to predict how drugs will behave in the eye as an alternative to experimenting on animals.

Main lines of research

  • Molecular diagnosis of patients with Retinitis Pigmentosa using high-throughput screening techniques (HRM and DNA arrays) and Next Generation Sequencing (targeted sequencing using panels of Retinitis Pigmentosa genes and/or Whole Exome Sequencing, WES).
  • Studies on Retinitis Pigmentosa mouse models.
    • Elements regulating the gene expression (microRNAs; (microRNAs, lncRNAs etc.).
    • In vitro and in vivo gene transfer assays.
  • Molecular study of molecular pathways involved in cataract development factors.
    • Implication of aquaporins 1 and 5 in cataract development.
    • Study of risk factors for posterior capsular opacification after cataract surgery (secondary cataract).
  • Development of computer simulated predictors for ocular pharmacodynamics.

Team Members

Name Surname Center E-mail
Arantxa Acera Osa UPV-EHU arantxa.acera@biodonostia.org
Txomin Alberdi Ibarloza Donostialdea IHO txomin.alberdiibarloza@osakidetza.eus
Lucía Bascarán Oteiza Donostialdea IHO lucia.bascaranoteiza@osakidetza.eus
Leire Escudero Arraras Biodonostia HRI leire.escudero@biodonostia.org
Leire Juaristi Eizmendi Donostialdea IHO leire.juaristieizmendi@osakidetza.eus
Araceli Lara López Biodonostia HRI araceli.lara@biodonostia.org
Itziar Martínez Soroa Donostialdea IHO itziar.martinezsoroa@osakidetza.eus
Javier Mendicute del Barrio Donostialdea IHO javier.mendicutedelbarrio@osakidetza.eus
Iñaki Rodríguez Aguirreche Donostialdea IHO ignacio.rodriguezaguirreche@osakidetza.eus
María Rodríguez Hidalgo Biodonostia HRI maria.rodriguezhidalgo@biodonostia.org
Miguel Ruiz Miguel Donostialdea IHO miguel.ruizmiguel@osakidetza.eus

 

Scientific Output

RETIC OFTARED ENFERFEDADES OCULARES
Código: RD16/0008/0027
Investigador Principal (IP): IÑAKI RODRIGUEZ AGUIRRECHE
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2017-01-01
Fecha de finalización: 2021-12-31
Importe Concedido: 22.907,50 €
CARACTERIZACION GENETICO-MOLECULAR DE LOS PACIENTES CON DISTROFIAS HEREDITARIAS DE LA RETINA DE LA C.A. DEL PAIS VASCO
Código: PI17/01413
Investigador Principal (IP): CRISTINA IRIGOYEN LABORRA
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2018-01-01
Fecha de finalización: 2022-06-30
Importe Concedido: 99.220,00 €
SINDROME PSEUDOEXFOLIATIVO:ESTUDIO CLINICO EPIDEMIOLOGICO Y MOLECULAR EN MUESTRAS PROCEDENTES DE CIRUGIA DE CATARATA Y GLAUCOMA
Código: PI18/00507
Investigador Principal (IP): JAVIER RUIZ EDERRA
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2019-01-01
Fecha de finalización: 2021-12-31
Importe Concedido: 75.020,00 €
CARACTERIZACION GENETICA DE LOS PACIENTES CON DISTROFIAS HEREDITARIAS DE RETINA DE EUSKADI
Código: 2018111062
Investigador Principal (IP): JAVIER RUIZ EDERRA; CRISTINA IRIGOYEN LABORRA
Entidad Financiadora: DEPARTAMENTO DE SALUD
Fecha de Inicio: 2018-12-14
Fecha de finalización: 2021-06-30
Importe Concedido: 72.212,00 €
AMNIOGEL BIOMATERIALES DE ULTIMA GENERACION EN MEDICINA REGENERATIVA OFTALMOLOGICA
Código: KK-2019/00086
Investigador Principal (IP): JAVIER MENDICUTE DEL BARRIO
Entidad Financiadora: DEPARTAMENTO DE DESARROLLO ECONÓMICO E INFRAESTRUCTURAS
Fecha de Inicio: 2019-03-01
Fecha de finalización: 2021-06-30
Importe Concedido: 71.125,00 €
IMPLANTACIÓN DE CLÍNICAS VIRTUALES DE RETINA MÉDICA (TELEOFTALMOLOGÍA) EN OSI DONOSTIALDEA
Código: 20BU209
Investigador Principal (IP): LEIRE JUARISTI EIZMENDI
Entidad Financiadora: OSI DONOSTIALDEA
Fecha de Inicio: 2019-09-01
Fecha de finalización: 2021-09-30
Importe Concedido: 13.491,00 €
BONO TECNOLOGICO 2019 - MIRAMOON. NUEVAS ESTRATEGIAS BASADAS EN TERAPIA FARMACOLOGICA PARA LAS DISTROFIAS HEREDITARIAS DE RETINA
Código: 0507/2019/0180
Investigador Principal (IP): JAVIER RUIZ EDERRA
Entidad Financiadora: FOMENTO DE SAN SEBASTIAN SA
Fecha de Inicio: 2019-11-01
Fecha de finalización: 2020-04-30
Importe Concedido: 12.500,00 €
MIRANEBT-LANZAMIENTO DE NEBT INVESTIGACION ORIENTADA AL DESARROLLO DE NUEVAS TERAPIAS FARMACOLOGICAS PARA LAS DISTROFIAS HEREDITARIAS DE LA RETINA
Código: ZL-2020/00780
Investigador Principal (IP): JAVIER RUIZ EDERRA
Entidad Financiadora: DEPARTAMENTO DE DESARROLLO ECONÓMICO E INFRAESTRUCTURAS
Fecha de Inicio: 2020-03-01
Fecha de finalización: 2020-12-31
Importe Concedido: 30.000,00 €
VALIDACION DE NUEVOS MODULADORES DE CALCIO COMO TERAPIA PARA LAS DISFROFIAS HEREDITARIAS DE LA RETINA
Código: DFG2020/104
Investigador Principal (IP): JAVIER RUIZ EDERRA
Entidad Financiadora: DIPUTACION FORAL GIPUZKOA
Fecha de Inicio: 2020-09-01
Fecha de finalización: 2022-02-28
Importe Concedido: 0,00 €